Advanced Biomed Inc. cash flow statement ADVB

Annual Quarterly

In fiscal 2026, which ended Jun 30, 2026, Advanced Biomed Inc. used $1.9 million of cash from operations, up 66.6% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Jun 30, 2025
Operating
Depreciation and amortization
—
0
Stock-based compensation
2
—
Operating cash flow
-2
+66.6%
-6
Investing
Capital expenditures
—
0
Investing cash flow
-3
-7818.1%
-0
Financing
Financing cash flow
2
-66.8%
6
Change in cash
Effect of exchange rate
-0
-104.8%
0
Net change in cash
-3
-951.0%
0
Free cash flow
—
-6
Per share
Free cash flow per share
—
-5.71
Ratios
Stock-based compensation to revenue
1,358.55%
—
Cash conversion
-0.29x
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
ADVB (Nasdaq)
Fiscal year ends
June 30
Incorporated in
NV
Headquarters
Reno, NV
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1941029

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.